Castle Biosciences (NASDAQ:CSTL) CFO Sells $192,080.00 in Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) CFO Frank Stokes sold 7,000 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $27.44, for a total value of $192,080.00. Following the transaction, the chief financial officer owned 52,483 shares of the company’s stock, valued at $1,440,133.52. This trade represents a 11.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Castle Biosciences Price Performance

Castle Biosciences stock opened at $27.12 on Friday. The stock’s 50 day moving average is $35.92 and its 200 day moving average is $31.49. Castle Biosciences, Inc. has a one year low of $14.59 and a one year high of $44.28. The firm has a market cap of $806.28 million, a P/E ratio of -31.91 and a beta of 1.09. The company has a debt-to-equity ratio of 0.02, a current ratio of 5.26 and a quick ratio of 5.11.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.08) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.23) by $0.15. The firm had revenue of $81.88 million during the quarter, compared to analyst estimates of $81.19 million. Castle Biosciences had a negative net margin of 7.02% and a negative return on equity of 0.89%. As a group, research analysts expect that Castle Biosciences, Inc. will post 0.44 EPS for the current year.

Hedge Funds Weigh In On Castle Biosciences

A number of institutional investors and hedge funds have recently made changes to their positions in CSTL. Amundi grew its stake in shares of Castle Biosciences by 15,811.5% in the 1st quarter. Amundi now owns 4,137 shares of the company’s stock valued at $79,000 after buying an additional 4,111 shares during the period. AQR Capital Management LLC raised its stake in Castle Biosciences by 548.9% during the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after buying an additional 115,907 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Castle Biosciences by 4.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after acquiring an additional 655 shares in the last quarter. Jones Financial Companies Lllp boosted its holdings in Castle Biosciences by 10,592.0% in the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after acquiring an additional 2,648 shares in the last quarter. Finally, Envestnet Asset Management Inc. grew its stake in Castle Biosciences by 1.0% in the second quarter. Envestnet Asset Management Inc. now owns 70,478 shares of the company’s stock valued at $1,439,000 after acquiring an additional 707 shares during the period. Institutional investors own 92.60% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on CSTL. Morgan Stanley upgraded shares of Castle Biosciences to a “buy” rating in a report on Monday, March 2nd. Canaccord Genuity Group increased their price target on Castle Biosciences from $37.00 to $50.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. Robert W. Baird lifted their price objective on Castle Biosciences from $41.00 to $44.00 and gave the stock an “outperform” rating in a research report on Friday, February 27th. Lake Street Capital raised their target price on Castle Biosciences from $35.00 to $52.00 and gave the stock a “buy” rating in a research note on Monday, January 12th. Finally, BTIG Research lifted their target price on Castle Biosciences from $38.00 to $50.00 and gave the stock a “buy” rating in a report on Friday, December 12th. Eight equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, Castle Biosciences has a consensus rating of “Moderate Buy” and a consensus price target of $47.57.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.